Article Text

Download PDFPDF
Using digital technology for home monitoring, adherence and self-management in cystic fibrosis: a state-of-the-art review
  1. Rebecca Jane Calthorpe1,
  2. Sherie Smith1,
  3. Katie Gathercole2,3,
  4. Alan Robert Smyth1
  1. 1Division of Child Health, Obstetrics and Gynaecology, University of Nottingham, Nottingham, UK
  2. 2School of Education, University of Leeds, Leeds, UK
  3. 3Person with Cystic Fibrosis, Leeds, UK
  1. Correspondence to Professor Alan Robert Smyth, Division of Child Health, Obstetrics & Gynaecology, University of Nottingham, Nottingham NG7 2UH, UK; alan.smyth{at}nottingham.ac.uk

Abstract

Digital healthcare is a rapidly growing healthcare sector. Its importance has been recognised at both national and international level, with the WHO recently publishing its first global strategy for digital health. The use of digital technology within cystic fibrosis (CF) has also increased. CF is a chronic, life-limiting condition, in which the treatment burden is high and treatment regimens are not static. Digital technologies present an opportunity to support the lives of people with CF. We included 59 articles and protocols in this state-of-the-art review, relating to 48 studies from 1999 until 2019. This provides a comprehensive overview of the expansion and evolution of the use of digital technology. Technology has been used with the aim of increasing accessibility to healthcare, earlier detection of pulmonary exacerbations and objective electronic adherence monitoring. It may also be used to promote adherence and self-management through education, treatment management Apps and social media.

  • cystic fibrosis
  • psychology
  • exercise
View Full Text

Statistics from Altmetric.com

Footnotes

  • Twitter @DrRCalthorpe

  • Contributors RJC and SS completed the systematic literature search and data extraction. KC wrote the review with all authors commenting on the final manuscript. In addition, KG also contributed to the review by the inclusion of the patients perspective throughout the article. ARS was the supervising author on this review, and is the corresponding author.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests ARS has provided consultancy for Vertex and holds a current unrestricted research grant from Vertex. He has taken part in clinical trials sponsored by Vertex, Raptor and Insmed. He has given lectures at meetings sponsored by Teva and Vertex.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.